Concor - instructions for use, reviews, analogs and forms of release (5 mg, 10 mg, 2.5 mg Kor) medications for the treatment of blood pressure, CHD, heart failure in adults, including during pregnancy. Side effect
In this article, you can read the instructions for using the drug Concor. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Concor in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Concor in the presence of existing structural analogues. Use for the treatment of hypertension, IHD, stable angina and heart failure in adults,as well as during pregnancy and lactation. Side effect and the use of alcohol with medicine.
Concor - selective beta1-adrenoblocker, without its own sympathomimetic activity, does not have a membrane-stabilizing action.
Has only a slight affinity for beta2-adrenoreceptors of smooth muscles of bronchi and vessels, as well as for beta2-adrenoreceptors involved in the regulation of metabolism. Therefore, Bisoprolol (the active substance of the Concor preparation) generally does not affect the resistance of the respiratory tract and the metabolic processes in which beta2-adrenergic receptors are involved.
The selective effect of the drug on beta 1-adrenergic receptors persists beyond the therapeutic range.
Bisoprolol does not have a pronounced negative inotropic effect.
Bisoprolol reduces the activity of the sympathoadrenal system by blocking the beta 1-adrenergic receptor of the heart.
With a single oral intake in patients with IHD without signs of chronic heart failure, bisoprolol reduces heart rate, reduces stroke volume of the heart and, as a result, reduces the ejection fraction and myocardial oxygen demand. With prolonged therapy, the initially increased OPSS decreases.Reduction of renin activity in blood plasma is considered as one of the components of antihypertensive action of beta-blockers.
The maximum effect of the drug is achieved 3-4 hours after ingestion. Even with the appointment of bisoprolol 1 time per day, its therapeutic effect persists for 24 hours due to the fact that its T1 / 2 from the blood plasma is 10-12 hours. As a rule, the maximum decrease in blood pressure is achieved 2 weeks after the start of treatment.
Pharmacokinetics
After ingestion, Concor almost completely (> 90%) is absorbed from the digestive tract. Eating does not affect bioavailability. Bisoprolol clearance is determined by the balance between excretion by the kidneys in an unchanged form (about 50%) and metabolism in the liver (about 50%) to metabolites that are also excreted by the kidneys.
Indications
- arterial hypertension;
- IHD: stable angina;
- chronic heart failure.
Forms of release
Tablets coated with 5 mg and 10 mg.
Tablets coated with 2.5 mg (Concor Cor).
Instructions for use and dosage
The drug is taken orally once a day. Tablets should be taken with a small amount of liquid in the morning before breakfast, during or after it.Tablets should not be chewed or ground into a powder.
Arterial hypertension and angina pectoris
The dose is selected individually, primarily taking into account the heart rate and the patient's condition.
As a rule, the initial dose is 5 mg once a day. If necessary, the dose can be increased to 10 mg once a day. In the treatment of hypertension and angina, the maximum recommended dose is 20 mg once a day.
Chronic heart failure
The standard treatment regimen for chronic heart failure includes the use of ACE inhibitors or angiotensin 2 receptor antagonists (in the case of intolerance to ACE inhibitors), beta-blockers, diuretics and, optionally, cardiac glycosides. At the beginning of the treatment of chronic heart failure, Concor requires a special phase of titration under regular medical supervision.
A precondition for the treatment with Concor is a stable chronic heart failure without signs of exacerbation.
Treatment with Concor begins with the following titration scheme.Individual adaptation may be required depending on how well the patient tolerates the prescribed dose, i.e., the dose can be increased only if the previous dose is well tolerated.
To ensure the appropriate titration process at the initial stages of treatment, it is recommended to use bisoprolol in the dosage form of a 2.5 mg tablet.
The recommended initial dose is 1.25 mg once a day. Depending on the individual tolerability, the dose should be gradually increased to 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg once daily. Each subsequent increase in the dose should be carried out at least 2 weeks later. If the increase in the dose of the drug is poorly tolerated by the patient, then a dose reduction is possible.
The maximum recommended dose for the treatment of chronic heart failure is 10 mg once a day.
During titration, regular monitoring of blood pressure, heart rate and degree of symptoms of chronic heart failure is recommended. The worsening of the symptoms of the course of chronic heart failure is possible already from the first day of application of the drug.
If the patient does not tolerate the maximum recommended dose of the drug, then the possibility of a gradual dose reduction should be considered.
During the titration phase or after it, temporary deterioration of the course of chronic heart failure, arterial hypotension or bradycardia is possible. In this case, it is recommended, first of all, to correct the doses of concomitant therapy. It may also require a temporary reduction in the dose of Concor or its cancellation. After stabilization of the patient's condition, a repeated titration of the dose should be performed, or the treatment should be continued.
Duration of treatment for all indications
Treatment with Concor is usually long-term.
Older patients do not need a dose adjustment.
Because There is not enough data on the use of Concor in children, it is not recommended to prescribe the drug to children under 18 years of age.
To date, there is insufficient data on the use of Concor in patients with chronic heart failure in combination with type 1 diabetes mellitus, expressed by impaired renal and / or liver function,restrictive cardiomyopathy, congenital heart disease or heart valve disease with severe hemodynamic disorders. Also, sufficient data have not yet been obtained regarding patients with chronic heart failure with myocardial infarction during the last 3 months.
Side effect
- bradycardia (in patients with chronic heart failure);
- exacerbation of symptoms of chronic heart failure (in patients with chronic heart failure);
- a feeling of cold or numbness in the limbs;
- marked decrease in blood pressure (especially in patients with chronic heart failure);
- orthostatic hypotension;
- dizziness;
- headache;
- loss of consciousness;
- depression;
- insomnia;
- hallucinations;
- reduction of tearing (should be considered when wearing contact lenses);
- hearing impairment;
- conjunctivitis;
- bronchospasm in patients with bronchial asthma or obstructive airways disease in the anamnesis;
- nausea, vomiting;
- diarrhea, constipation;
- muscle weakness;
- muscle cramps;
- violation of potency;
- itching;
- rash;
- hyperemia of the skin;
- allergic rhinitis;
- asthenia (in patients with chronic heart failure);
- increased fatigue.
Contraindications
- acute heart failure;
- chronic heart failure in the stage of decompensation, requiring treatment with drugs with a positive inotropic effect;
- cardiogenic shock;
- AV-blockade of 2 and 3 degrees, without the pacemaker;
- SSSU;
- sinoatrial blockade;
- marked bradycardia (heart rate <60 bpm);
- marked decrease in blood pressure (systolic blood pressure <100 mmHg);
- severe forms of bronchial asthma and COPD in history;
- severe violations of peripheral arterial blood circulation, Raynaud's disease;
- pheochromocytoma (without simultaneous use of alpha-blockers);
- metabolic acidosis;
- age under 18 years (insufficient data on efficiency and safety);
- hypersensitivity to the components of the drug.
Application in pregnancy and lactation
The use of Concor in pregnancy is possible only if the intended benefit to the mother exceeds the potential risk to the fetus.
Beta-adrenoblockers reduce blood flow in the placenta and can affect the development of the fetus.Blood flow in the placenta and uterus should be carefully monitored, and the growth and development of the unborn child should be monitored, and alternative therapeutic measures taken in case of undesirable manifestations in relation to pregnancy or fetus. You should carefully examine the newborn after delivery. In the first 3 days of life, bradycardia and hypoglycemia may occur.
There is no data on bisoprolol and breast milk. Concor is not recommended for women during lactation. If you need to use the drug during lactation, breastfeeding should be discontinued.
special instructions
The patient should not abruptly discontinue treatment and change the recommended dose without first consulting a doctor, as this can lead to a temporary deterioration in the heart. Treatment should not be interrupted suddenly, especially in patients with ischemic heart disease. If discontinuation of treatment is necessary, the dose should be reduced gradually.
Three - and tetracyclic antidepressants, antipsychotics (antipsychotics), ethanol (alcohol), sedative and hypnotic drugs increase the depression of the central nervous system.
At the initial stage of treatment with Concor, patients need constant medical supervision.
Caution should be used in patients with diabetes mellitus with significant fluctuations in blood glucose (symptoms of severe hypoglycemia, such as tachycardia, palpitations or excessive sweating may be masked), in patients on a strict diet, with desensitizing therapy, AV-blockade 1 degree , Prinzmetal angina, violations of peripheral arterial blood flow of mild and moderate degree (at the beginning of therapy there may be an increase in symptoms), with psoriasis (including anamn eze).
Respiratory system: with bronchial asthma or COPD, simultaneous application of bronchodilating agents is indicated. In patients with bronchial asthma, an increase in airway resistance may be required, which requires a higher dose of beta2-adrenomimetics.
Allergic reactions: beta-adrenoblockers, including Concor preparation, can increase sensitivity to allergens and the severity of anaphylactic reactions due to weakening of adrenergic compensatory regulation under the action of beta adrenoblockers. Epinephrine (epinephrine) therapy does not always produce the expected therapeutic effect.
When conducting general anesthesia, the risk of blockade of beta-adrenergic receptors should be considered. If it is necessary to discontinue therapy with Concor before surgery, it should be done gradually, and completed 48 hours before the general anesthesia. An anesthetist should be warned that the patient is taking Concor.
In patients with pheochromocytoma, Concor can be prescribed only against the background of the use of alpha-blockers.
When treated with Concor, the symptoms of hyperthyroidism may be masked.
Impact on the ability to drive vehicles and manage mechanisms
Concor does not affect the ability to drive vehicles according to the results of the study in patients with ischemic heart disease. However, due to individual reactions, the ability to drive a car or work with technically complex machinery can be disrupted. This should be paid special attention at the beginning of treatment, after changing the dose, as well as with the simultaneous use of alcohol.
Drug Interactions
The effectiveness and tolerability of bisoprolol may be affected by the simultaneous use of other drugs.This interaction can also occur when two drugs are taken in a short time. The physician should be informed about the use of other medicines, even if the application is carried out without a prescription.
Unrecommended combinations
Treatment of chronic heart failure
Class 1 antiarrhythmics (eg, quinidine, disopyramide, lidocaine, phenytoin, flecainide, propafenone), while being used with bisoprolol may reduce AV conduction and contractility of the heart.
All indications for the use of the drug Concor
Blockers of slow calcium channels like Verapamil and, to a lesser extent, diltiazem, with simultaneous application with bisoprolol can lead to a decrease in myocardial contractility and disturbance of AV conduction. In particular, intravenous administration of verapamil to patients taking beta-blockers can lead to severe arterial hypotension and AV blockade. Hypotensive agents of central action (such as clonidine, methyldopa, moxonidine, rilmenidine) can lead to a decrease in heart rate and a decrease in cardiac output, as well as to vasodilation due to a decrease in the central sympathetic tone.Abrupt cancellation, especially before the abolition of beta-blockers may increase the risk of developing "ricochet" hypertension.
Combinations requiring special care
Treatment of arterial hypertension and angina
Antiarrhythmic drugs of the first class (eg, quinidine, disopyramide, lidocaine, phenytoin, flecainide, propafenone) with simultaneous application with bisoprolol may reduce AV conduction and contractility of the myocardium.
All indications for the use of the drug Concor
Slow calcium channel blockers, dihydropyridine derivatives (eg, nifedipine, felodipine, amlodipine) with simultaneous use with bisoprolol may increase the risk of developing hypotension. In patients with chronic heart failure, the risk of subsequent deterioration of the contractile function of the heart can not be ruled out.
Antiarrhythmic drugs of the third class (for example, amiodarone), when used concomitantly with Concor, may increase the disturbance of AV conduction.
The action of beta-blockers for topical application (eg, eye drops for the treatment of glaucoma) can enhance the systemic effects of bisoprolol (lowering blood pressure, reducing heart rate).
Parasympatomimetics with simultaneous application with bisoprolol may increase the disturbance of AV conduction and increase the risk of developing bradycardia.
When used concomitantly with the drug Concor may increase hypoglycemic action of insulin or hypoglycemic agents for oral administration. Symptoms of hypoglycemia, in particular tachycardia, can be masked or suppressed. Such interaction is more likely when using non-selective beta-blockers.
Means for general anesthesia can increase the risk of cardiodepressive action, leading to arterial hypotension.
Cardiac glycosides with simultaneous application with bisoprolol may lead to an increase in the timing of the impulse, and thus to the development of bradycardia.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are able to reduce the hypotensive effect of Concor.
Concurrent use of Concor with beta-adrenomimetics (eg, isoprenaline, dobutamine) can lead to a decrease in the effect of both drugs.
The combination of bisoprolol with adrenomimetics that affect alpha and beta-adrenergic receptors (eg, norepinephrine,epinephrine) can enhance the vasoconstrictor effects of these drugs, due to the effect on alpha-adrenergic receptors, leading to an increase in blood pressure. Such interaction is more likely when using non-selective beta-blockers.
Antihypertensives, as well as other agents with a possible antihypertensive effect (for example, tricyclic antidepressants, barbiturates, phenothiazines) can enhance the hypotensive effect of bisoprolol.
Mefloquine with simultaneous application with bisoprolol can increase the risk of bradycardia.
MAO inhibitors (with the exception of MAO B inhibitors) can enhance the antihypertensive effect of beta-blockers. Simultaneous application can also lead to the development of hypertensive crisis.
Analogues of Concor drug
Structural analogs for the active substance:
- Aritel;
- Aritel Cor;
- Bidop;
- Biol;
- Biprol;
- Bisogamma;
- Bisocardium;
- Bisomore;
- Bisoprolol;
- Bisoprolol-Lugal;
- Bisoprolol-Prana;
- Bisoprolol-ratopharm;
- Bisoprolol-Teva;
- Bisoprolol hemifumarate;
- Bisoprolol fumarate;
- Concor Cor;
- Corbis;
- Cordinorm;
- Coronale;
- Niperten;
- Thyrez.
Similar medicines:
Other medicines:
- Papaverin - instructions for use, reviews, analogs and formulations (40 mg tablets, 20 mg suppositories, injections (injections)) for the treatment of spasms in adults, children and pregnancy
- Detraleks - instructions for use, analogs, reviews and release form (tablets of 500 mg) of the drug for the treatment of hemorrhoids, venous disorders in adults, including during pregnancy
- Enterosgel - instructions for use, analogs, reviews and release forms (paste and gel) drugs for the treatment of intoxications, dysbiosis, allergies and diarrhea in adults, children (including infants and newborns) and during pregnancy. Composition